drugset / Trial / NCT05458076

A Study of QLS1128 and in Combination With Ritonavir in Healthy Participants

NCT05458076 ↗

Phase 1 Unknown 86 enrolled Qilu Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A study to evaluate safety, tolerability and pharmacokinetics of QLS1128 sustained-release tablets and in combination with ritonavir tablets in healthy participants

Timeline

Start
2022-07-03
Primary completion
2022-09-06
Completion
2022-09-06

Drugs

EvaluationDrugModalityDoseRoute
Subject QLS1128 Unknown — —
Subject Ritonavir Other / unclassified — —

Indications